Abstract
Objective: To investigate the effects of continuous renal replacement therapy (CRRT) on traditional and novel multi-dimensional serum biomarkers including inflammatory cytokines, immune regulation markers, endothelial injury markers, cellular damage indicators, and clinical symptoms in patients with sepsis. Method: A retrospective collection was conducted on 116 sepsis patients treated with CRRT in the hospital from March 2019 to June 2024 as the observation group; 219 sepsis patients who received conventional treatment during the same period were matched with propensity score in a 1:1 ratio, and 116 patients were selected as the control group. Two groups of patients were observed and compared for TNF-α, IL-4, CRP, Presepsin, IL-6, NGAL, PD-L1, IL-10, mHLA-DR, Ang-2, sTM, histones, mtDNA, ADM, suPAR, and clinical symptom related indicators after treatment. COX regression analysis was utilized to investigate the influencing factors of 28 d survival in sepsis patients after treatment. Results: After treatment, the TNF-α, IL-4, CRP, Presepsin, IL-6, NGAL, PD-L1, IL-10, Ang-2, sTM, histones, mtDNA, ADM, and suPAR levels in the observation group were significantly lower than those in the control (*p*<0.05), while mHLA-DR expression was higher (*p*<0.05). The acute physiology and chronic health (APACHE II) score, sequential organ failure score (SOFA), body temperature, heart rate, and respiratory rate (RR) levels in the observation were also lower than control, but the oxygenation index (PaO~2~/FiO~2~) and urine output were higher (*p*<0.05). After 28d-treatment, the survival rates of patients in the control and observation were 65.52% and 81.90%. In COX analysis, septic shock, lactate, IL-4, CRP, Presepsin, IL-6, PD-L1, Ang-2, APACHE II score, RR, PaO~2~/FiO~2~, and CRRT were all factors affecting the 28 d survival of sepsis patients after treatment. Conclusion: During routine treatment of sepsis patients, CRRT can comprehensively alleviate inflammatory reactions, improve immune dysfunction, reduce endothelial and cellular damage, promote the elimination of sepsis related symptoms, and occupy a vital position in improving patient prognosis through multi-dimensional biomarker modulation.
Keywords
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.